Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

Association between chemotherapy use and clinical outcomes in young BRCA carriers with T1N0 breast cancer: Results from an international cohort study.

Filipa Lynce, Eva Blondeaux, Virginia Delucchi et al. Jun 01, 2025 pp. 541-541 10.1200/jco.2025.43.16_suppl.541

541 Background: Systemic treatment decisions for young BRCA carriers with small node-negative breast cancers present unique challenges due to limited evid...

A randomized controlled trial of cognitive behavioral therapy and bright light therapy for insomnia and fatigue during breast cancer treatment: SleepCaRe trial.

Joshua F. Wiley, Trang Thuy Do, Jordan Maccora et al. Jun 01, 2025 pp. 12009-12009 10.1200/jco.2025.43.16_suppl.12009

12009 Background: Women on chemotherapy for breast cancer (BC) report high levels of insomnia and fatigue. This trial aimed to test the main effects of Co...

Quantifying clinical harm and financial waste from failure to deploy personalized medicine for patients with metastatic non-small cell lung cancer in the United States.

Scott David Ramsey, Kristen Migliaccio-Walle, David L Veenstra et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20687

e20687 Background: Biomarker panel testing for newly diagnosed metastatic non-small cell lung cancer (mNSCLC) as recommended by the National Comprehensive...

Evaluation of the effectiveness and safety of disitamab vedotin for HER2-expressing advanced or recurrent gynecological cancers.

Lei Yuan, Yiting Bao Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17512

e17512 Background: Recent evolution of treatment landscape in advanced or recurrent gynecological cancers has led to novel treatments such as antibody-dru...

Evolving global burden and trend of cervical cancer in G20 countries: Age, sex, regional disparities from 1990-2021.

Jahnavi Chaudhari, Dhruvkumar Gadhiya, Shravani Gowd Venu Prakash et al. Jun 01, 2025 pp. 5541-5541 10.1200/jco.2025.43.16_suppl.5541

5541 Background: Cervical Cancer (CC) is the 6 th leading cause of death and 4 th leading cause of disabil...

A retrospective study assessing the efficacy of combined transarterial chemoembolization and microwave ablation in the treatment of large, unresectable hepatocellular carcinoma (≥5 cm).

Yang Fang, Huiying Cui, Songnan Zhang Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16274

e16274 Background: Unresectable large hepatocellular carcinoma (HCC) ≥5 cm without vascular invasion or extrahepatic metastasis, transarterial chemoemboli...

Multiomic analysis of cutaneous squamous cell carcinoma (cSCC) and association with response to anti-PD1 therapy (PD1).

Yu-Ju Kuo, Tuba Nur Gide, Yizhe Mao et al. Jun 01, 2025 pp. 9585-9585 10.1200/jco.2025.43.16_suppl.9585

9585 Background: PD1 induces a durable response and improves the survival of patients (pts) with advanced cSCC; however, about 40% of pts are resistant to...

Applying learning science principles (LSP) through a simulation session (SIM) for oncology trainees (OT) about fertility preservation (FP) in patients (pts) with cancer and treatment (tx) of pregnant pts (TPP) with cancer.

Tanmayi Pai, Guilherme Sacchi De Camargo Correia, Ewa Maria Wysokinska et al. Jun 01, 2025 pp. 9029-9029 10.1200/jco.2025.43.16_suppl.9029

9029 Background: Addressing guideline concordant FP and TPP with cancer is challenging, especially for OT. SIM, a well-known education tool, has not been...

Income and location divide in myeloma outcomes: A call for equitable care.

Jerry Kenmoe, Alexander Rabadi, Arvind Kunadi Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e19544

e19544 Background: Myeloma, a hematologic malignancy with rising incidence, has seen significant advancements in treatment over the past two decades. Howe...

Surgical debulking versus non-surgical management for the control of carcinoid syndrome in metastatic small bowel neuroendocrine tumors.

Rushabh Gujarathi, Joseph Tobias, Theodoros Michelakos et al. Jun 01, 2025 pp. 4147-4147 10.1200/jco.2025.43.16_suppl.4147

4147 Background: Somatostatin analogues (SSAs) are first-line systemic therapeutics for tumor- and symptoms control in well-differentiated small bowel neu...

Global trends and regional disparities in young-onset breast cancer: Age-specific patterns from 1990 to 2021.

Muzamil Khan, Waseem Nabi, Nouman Aziz et al. Jun 01, 2025 pp. 568-568 10.1200/jco.2025.43.16_suppl.568

568 Background: Young-onset breast cancer (YOBC), defined as breast cancer in women under 40, is a growing global health concern with unique biological an...

Effects of marital status on survival in patients with colorectal cancer.

Lisa Liu, Supriya Peshin, Alvaro Zevallos Barboza et al. Jun 01, 2025 pp. 3628-3628 10.1200/jco.2025.43.16_suppl.3628

3628 Background: Demographic factors such as marital status have been shown to have differential effects on cancer outcomes. It has been shown that marrie...

Updated efficacy and safety of entrectinib in children with extracranial solid or primary central nervous system (CNS) tumors harboring <i>ROS1</i> fusions.

Ami V. Desai, Huanmin Wang, Ellen M. Basu et al. Jun 01, 2025 pp. 10050-10050 10.1200/jco.2025.43.16_suppl.10050

10050 Background: Entrectinib is a TRK and ROS1 inhibitor that has shown rapid and durable responses in children with NTRK1/2/3 or...

Outcomes of an electronic patient-reported outcomes (ePRO)–based symptom management program (eSyM): A cluster randomized trial.

Michael J. Hassett, Hajime Uno, Angela C. Tramontano et al. Jun 01, 2025 pp. 11001-11001 10.1200/jco.2025.43.16_suppl.11001

11001 Background: Although ePROs have been shown to reduce resource utilization and improve outcomes among people with cancer, they have not been widely a...

RACED (Reduction of Cervical Cancer Disparities): The impact of navigators and racial literacy training.

Abna Faustina Sousa Vieira, Janaína Santos Paulista, Mateus Fonseca de Gouvea Franco et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps1660

TPS1660 Background: Cervical cancer is the third most prevalent cancer in Brazilian women. Approximately 17,000 new cases are expected for Brazil’s 2023-2...

Survival outcomes of Epstein-Barr virus-positive diffuse large B-cell lymphoma, not otherwise specified: Results from Latin American and United States cohorts.

Jose Concepcion-Holguin, Denisse Angélica Castro, Zijun Xu-Monette et al. Jun 01, 2025 pp. 7045-7045 10.1200/jco.2025.43.16_suppl.7045

7045 Background: Epstein-Barr virus-positive diffuse large B-cell lymphoma (EBV+ DLBCL), not otherwise specified, is rare in North America and Europe (2–4...

Hemoglobin level and neutrophil-to-lymphocyte ratio as prognostic peripheral blood markers of survival outcomes in sacituzumab govitecan therapy for mTNBC in Polish female cohort.

Małgorzata Pieniążek, Anna Polakiewicz-Gilowska, Manuela Las-Jankowska et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13152

e13152 Background: Hemoglobin (Hb) level and the neutrophil-to-lymphocyte ratio (NLR) are key prognostic factors in breast cancer, influencing survival an...

Envafolimab and chidamide in combination with GEMOX as first-line treatment for advanced and metastatic biliary tract cancer (B-Enefits/SCOG-B001): A single-arm, exploratory, phase 2 trial.

Wei Li, Kai Chen, Xiaofeng Chen et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16231

e16231 Background: Biliary tract cancer (BTC) is a rare malignant tumor with poor prognosis. Envafolimab is a light-chain deficient PD-L1 antibody. Chidam...

Efbemalenograstim alfa for the primary/secondary prophylaxis of intermediate-risk febrile neutropenia (FN) chemotherapy regimen with risk factors in patients with non-small cell lung cancer (NSCLC): A randomized, multicenter, exploratory clinical trial.

Mengjie Li, Dingzhi Huang, Tianhui Gao et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20560

e20560 Background: Neutropenia is a very common dose-limiting toxicity of chemotherapy. The extent and duration of neutropenia can variably affect the cli...

Implementation and execution of nationwide molecular tumor boards (MTBs) in resource-limited settings: The “Molecular Thursdays” initiative.

Breno Jeha Araújo, Leonard Silva, Amanda Rodrigues et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13895

e13895 Background: The increased access to broad next-generation sequencing (NGS) panels in routine oncology care has created a demand for education in mo...

Immunotherapy in patients with early-stage microsatellite instable (MSI-H)/mismatch repair deficient (dMMR) colorectal cancer (CRC) treated in a community setting.

Simranjit Sekhon, Elizabeth John, Heather Greene et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15668

e15668 Background: MSI-H/dMMR cancers represent 10-15% of early-stage colorectal cancer (CRC) and respond well to immune checkpoint therapy. However, clin...

A randomized controlled trial comparing conversion surgery with palliative chemotherapy in patients with initially unresectable cStage IVB/pStage IV advanced gastric cancer who presented remarkable response to chemotherapy: JCOG2301 (Conversion study).

Itaru Yasufuku, Masanori Terashima, Naoki Takahashi et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps4205

TPS4205 Background: Conversion surgery is a surgical treatment for patients with initially unresectable cStage IVB gastric cancer who presented remarkable...

Real-world (rw) study to identify disparities in outcomes for patients (pts) with early-stage resected NSCLC who received biomarker-targeted adjuvant treatment (BTRx).

Raymond U. Osarogiagbon, Robert Hsu, Melinda Laine Hsu et al. Jun 01, 2025 pp. 8071-8071 10.1200/jco.2025.43.16_suppl.8071

8071 Background: BTRx improves survival of pts with resected early-stage NSCLC, making thorough biomarker testing critical in this setting. Disparities in...

Trends in mortality due to laryngeal carcinoma: A systemic analysis of the Global Burden of Disease 2021.

Jehad Feras AlSamhori, Shree Rath, Muzamil Khan et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18141

e18141 Background: Laryngeal cancer is among the most common respiratory system malignancies. While significant strides have been made in its treatment ov...

Real world data: Survival outcomes of patients with poor prognosis metastatic germ cell tumours (GCT) within a large tertiary UK centre.

Kabo Abdirazack Hadji Mohamed, Jasmin Mahil, Kathryn Herring et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17021

e17021 Background: Patients categorised as having poor prognosis GCT, as per the International Germ Cell Cancer Collaborative Group (IGCCCG) risk classifi...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page